CDKN2A and neoplasm: When analyzing breast cancer tumors, including IDCs and ILCs, we observed new mutations in CDKN2A, RB1, CCND2, and CCND3 in the brain metastases of four IDCs, but not in their primary tumor counterparts (Figure 2A).